Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
shows .56 but says .51. needs a few more days trading then maybe it can lift. don't really trust ULU anymore.. hasn't held real gains in years.
Nice close....
All of the claims and innuendo in this posting are false. It was written by Michael S. Wachs of CEOcast. As revealed by Barron’s, Wachs is a “convicted financial felon” who is banned for life from the securities and banking industries. Wachs and two other “big time financial felons” run Socius Capital Group LLC, a “fake fund” that seeks to steal business from the three legitimate firms slammed in Wachs’ posting.
As officially disclosed by FINRA, Wachs “misappropriated $20,800,000 in proceeds by means of false and fraudulent pretenses, representations, and promises for the sale of certain of his member firm’s assets and then diverted the proceeds to himself and others.” Socius partner Terren S. Peizer is infamous for his role as “left hand man” to convicted felon Michael Milken in the Drexel Burnham Lambert junk bond scandal. Peizer avoided doing hard time by turning “states evidence” and testifying against his mentor. The third member of the Socius team is convicted felon Richard Josephberg, recently paroled from prison after 21 convictions for fraud, conspiracy and tax evasion over 29 years. In between visits to his parole officer, Josephberg promotes Socius CG and Optimus Capital Partners to unsuspecting CEO’s, using aliases like Rick Berg and Rich Joseph. He is also banned for life from the securities industry. It is no wonder that Wachs, Peizer and Josephberg’s names appear nowhere on Socius’s website.
Socius has been repeatedly sued by issuers for taking their stock and then failing to fund as promised. The three felons appear to be growing increasingly desperate, as word spreads that Socius does not have anywhere near the capital they claim, that the source of their money is a criminal enterprise, and that any company doing business with them risks asset forfeiture and SEC investigation. Do not believe Socius’ anonymous bashing of their legitimate competitors.
ULU 0.37 with euro zone partnership:
ULURU announces Altrazeal agreement for the European market (ULU) 0.32 : Co announced that it has signed a binding letter of intent with Melmed Holdings AG, a company based in Switzerland, to license Altrazeal for the European Union. Under the terms of the agreement ULURU will license the European Union rights to a subsidiary of Melmed Holdings AG specifically formed to market Altrazeal in the European Union. In exchange for the license ULURU will receive a licensing payment and a 25% interest in the Altrazeal marketing subsidiary that have a combined value of ~$2.5 mln. In addition, ULURU will supply Altrazeal at a price equal to 30% of the European sales price and will receive a royalty on sales within the territory.
A MUST READ !!!! For any Uluru subscriber
The downturn in the stock market was especially severe in the third quarter, as sovereign debt fears in Europe and recession concerns in the United States caused the S&P 500 to decline 14%, the worst quarterly performance since the financial crisis of 2008. While equities suffered globally, no more pain was felt than by those who owned small and microcap stocks. The Russell Microcap Index plunged more than 20% in the third quarter, and is down more than 20% for the year. However, out of declines come opportunities, and the downturn in tiny stocks has spawned a new breed of predatory investors who prey on small, unsophisticated cash-starved companies the same way that some animals eat their young. Although funds like NIR Group have shut down due to SEC lawsuits and issuer litigation, other groups such as JMJ Financial, Ironridge Global Partners and Southridge Capital Management have taken their place. We’ll take a brief look at each and why when you see them in your portfolio you should run the other way.
JMJ Financial
The group, founded by Justin Keener, who bills himself as a “lifetime entrepreneur” according to its web site, typically invests $400,000-$1,250,000 up-front in small companies. The structures are generally convertible transactions, in which Notes are converted into equity at a time of JMJ’s choosing. So far, so good. The “toxic” part however is that there is no floor. When JMJ converts, it is almost always at prices between 50-80% of the market price for the stock, wherever the stock is at the time it chooses to convert. The “good news” for investors is that the conversion opportunity doesn’t generally occur for six months, as it purchases securities that are restricted. However, once the conversion opportunity occurs, the results are often not pretty.
One such company who appears to be a “repeat offender” with JMJ is Cord Blood America (OTCBB: CBAI), a company that provides collection and storage of stem cells. On January 12, 2011, the Company issued a $1,050,000 "Convertible Promissory Note" to JMJ according to regulatory filings with the SEC. The three-year Note bears interest in the form of a one- time interest charge of 10%, payable on the maturity date. The problem is that the Note is also convertible at any time into common stock at a per share conversion price equal to 85% of the average of the 5 lowest traded prices for the Company's common stock in the 20 trading days previous to the effective date of each such conversion. In essence, regardless of when JMJ converts, the lender is assured of at least a 15% discount to the price at the time of conversion, and likely a lot more than that as it can pick the lowest prices during the conversion price. Not surprisingly, the company said in the same regulatory filing with the SEC it owed the investor liquidated damages from a previous transaction. The penalties included a reduced conversion price, and an increase in principal of more than 30%. The stock has lost more than 90% of its value since the middle of May this year, just two months before JMJ could start converting. Unfortunately, many of the other stocks that JMJ has funded have experienced similar results.
Ironridge Global Partners
Perhaps the most predatory of all groups is the newest. Co-founded earlier this year by John Kirkland, an attorney who worked for Marc Dreier, currently serving 20 years in jail after pleading guilty to a $700 million fraud and Brendan T. O’Neil who has run two funds that have folded in the last three years, Ironridge bills itself, according to its web site, as “supplying innovative financing solutions and flexible capital, as it seeks to unlock the full potential of cash-constrained businesses.” There is certainly some truth to that statement, as the companies it has completed deals with seem on the verge of going out of business. Ironridge usually doesn’t fund the company until after it sells the stock, as the filings show that payments are often not made until at least 20 days after they have received free-trading shares (imagine borrowing money from somebody and having to provide them with the money to make your loan before you receive any proceeds from them). The destruction in stocks they have completed transactions with makes the devastation from Hurricane Irene seem tame by comparison. Just two weeks ago, Uluru (NYSE: ULU) announced a “$1.6 million financing at a premium to market with Ironridge.” The problem is that the company neither received $1.6 million, nor was the deal done at a premium. The details in the 8-k suggest that the press release was misleading, as the company will receive proceeds only after a certain dollar amount of stock trades, and Ironridge’s actual cost to buy the stock is a fraction of the advertised price. Investors don’t seem fooled, as ULU’s stock is down nearly 50% in two weeks since the deal was announced. Less than two weeks after announcing the deal with Ironridge, the regulatory arm of the NYSE AMEX notified Uluru that it was not in compliance with listing standards and that it faced delisting. Uluru, like all of the companies Ironridge has completed transactions with, currently has a nominal market capitalization, in this case less than $2 million.
Uluru is not the only company in Ironridge’s portfolio facing delisting. PositiveID Corporation (OTCBB: PSID) was delisted from the Nasdaq less than five weeks after entering into “Strategic Financings for Up to $13.8 Million at a Premium to Current Share Price” with Ironridge. Shortly after the announcement, however, the company acknowledged in an 8-k filing that it did not receive the funds it had anticipated and that the price of the deal was being revised lower (think floorless financing). According to the filing made nearly two months after the deal was announced, the company has still not received the $1.5 million it was anticipating receiving as the first part of the funding. Approximately one month after the deal was announced, the CEO resigned. The stock has lost approximately 60% of its value in two months since the deal was announced.
Apparently inking a deal with Ironridge is not a career-enhancing move for a CEO. Less than three weeks after announcing an initial round of funding of approximately $1.12 million from Ironridge, the CEO of High Plains Gas (OTCBB: HPGS) resigned in the wake of the stock’s loss of more than 65% of its price. Like other companies which have done business with Ironridge, neither High Plains nor its creditors had received funding weeks after the deal was completed. Imagine losing your job, destroying your stock and not receiving proceeds after all of that. On average, from the time a regulatory filing was made announcing a deal with Ironridge, companies saw their stocks lose more than half their value within one month.
Southridge Capital Management
While Ironridge in a short period of time has become notorious for destroying small companies, Southridge has been at it for much longer. Apparently, the SEC decided that if companies couldn’t protect themselves from the group that it would step in and attempt to halt the predatory investment practices. Less than one year ago, both the SEC and Connecticut filed suit against the fund, accusing it of filing “ false financial statements and other violations of the funds’ private placement memoranda and charging excessive fees to the funds’ investors,” according to the state’s complaint, “based on misleading and fraudulent valuations of the assets Southridge managed on behalf of the funds and their investors.”
The fund’s investors are not the only ones however taking it to court. Hyperdynamics sued Southridge in a Georgia court charging that it “conspired to engage in fraud and market manipulation involving toxic convertible financing transactions with companies seeking private placement investors. According to Hyperdynamics, Southridge used an offshore financial structure to conceal both the true identity of, and the relationship between, the Defendants when preying upon unsuspecting businesses seeking financing. The Defendants are alleged to enter into toxic convertible financing agreements with the then-present intent to surreptitiously use short sales and naked short sales to manipulate the value of the company's stock by driving the price downward, and to then acquire a majority position in the company upon the conversion of the investor's preferred securities to common stock. Hyperdynamics is just one of many companies who has sued Southridge for destroying its business.”
Limited access to the capital markets has made for tough times for small companies. Many large and small companies have seen significant declines in the price of their stocks. But dealing with these groups seems to represent the last step before a company shuts its doors, leaving investors holding worthless securities. If you see one of the companies in your portfolio announce a deal with one of these groups, beware that it is likely not one it appears to be and that the stock and your bankroll is likely to suffer significant damage. Caveat emptor!
Me too. It's kind of like a dog going back to his vomit here, Lol. Tempting to put bad money to work at the same place. These sellers have totally jacknifed this truck with AMEX BS. You would think a CEO running a company would know better than to do a R/Split, what an idiot imo. I've never seen one successfully done just to maintain trading status on BS AMEX. Now, another letter from the exchange to OTC:BB most likely. This company needs a leader IMO> take to OTC and start over, he11 there's only 5m shares in the frickn float!
D MODE
got out a while ago...took the hit and moved on. Happens sometimes
Still believe?
D MODE
This scam still running?
ULU $0.53 with financing found, The terms:
ULURU enters into strategic financings of up to $1.6 million at a premium to current share price (ULU) 0.51 : Co announced it has entered into agreements for investment commitments with Ironridge Global BioPharma and its affiliates, under which Ironridge has committed in two transactions to purchase common and preferred stock totalling up to $1.6 mln. One of the transactions includes a purchase of up to $650,000 in convertible, redeemable, preferred stock with a 7.5% dividend. The preferred stock is convertible into shares of the co's common stock at a minimum conversion price of $0.70, which represents a premium of ~37 percent over the closing price on September 14, 2011. In the second financing, the co may issue up to $969,000 of registered common stock, subject to certain conditions, at a price per share equal to $ 0.50, 102% of the closing bid price of the co's common stock on September 14, 2011, in exchange for cash or a secured promissory note issued by the investor.
Conference call here going to be interesting.
It should pop someday...lol
DMODE
bad day today...this isnt turning out well...hahah Hold and wait at this point now
Looking for this to make a move again... into the dollar range. I was wrong about last week but am going to be patient here. CEO loaning them money is a good sign
Got some nice MM activity here today...something might be up
FDA approval news will change the game ..
It is anticipated that a 510(k) application will be filed with the FDA
in approximately 90 days. Assuming no extended delays in FDA review,
approval of Altrazeal® exSALT(TM) could occur as early as the third
quarter of 2011. The antimicrobial segment of the North American
advanced wound care market is projected to grow in the next 5 years to
be in excess of $750 million with annual growth rates above 15%.
http://www.redorbit.com/news/health/1981422/uluru_inc_announces_agree...
It is anticipated that a 510(k) application will be filed with the FDA
in approximately 90 days. Assuming no extended delays in FDA review,
approval of Altrazeal® exSALT(TM) could occur as early as the third
quarter of 2011.
http://www.redorbit.com/news/health/1981422/uluru_inc_announces_agreement_with_exciton_to_develop_antimicrobial_dressing/
Altrazeal..USFDA approval/Amelexanox for CANCER SORE..
http://www.uluruinc.com/press_releases/ULURU_Inc_Announces_Filing_of_a_510_k_%20for_Altrazeal_Collagen.pdf
Amlexanox 5% paste is used for the treatment of cancer sores. A Phase IV clinical study conducted in Northern Ireland and results confirmed that amlexanox 5% paste was effective in preventing the formation of an ulcer when used at the first sign or symptom of the disease. As of December 31, 2010, Contract Pharmaceuticals Ltd. Canada is the Company’s contract manufacturer for all markets, including the United States.
ULU PRICE TGT $2.16 COMPANY BUY BACK COMMON SHARES The company may force conversion of the convertible note if the common stock trades for a defined period of time at a price greater than $2.16.
ULU news, FDA approval is coming:
ADDISON, Texas, May 4, 2011 /PRNewswire/ -- ULURU Inc. (NYSE AMEX: ULU) announced today that it has filed a 510(k) application with the U.S. Food and Drug Administration to obtain marketing authorization for Altrazeal® Collagen.
Collagen containing wound care products represent a growing segment of the advanced wound care market. Collagen stimulates cellular migration and contributes to new tissue development. Collagen dressings encourage the deposition and organization of newly formed collagen, creating an environment that fosters healing. Biomaterials with collagen stimulate the wound healing cascade, recruiting specific cells during this process and ultimately, enhance wound healing.
Commenting on the Company's 510(k) application, Kerry P. Gray, President and CEO of ULURU Inc., stated, "Altrazeal® Collagen is an important line extension for our wound care franchise. Initial studies indicate that combining Altrazeal® with collagen provides accelerated wound healing compared to collagen alone, potentially providing additional synergistic benefits. The collagen market segment is a growing and important category within advanced wound care. Having Altrazeal® Collagen available will enable our sales representatives to provide an additional alternative therapy to the wound care professional to treat chronic wounds."
no shit huh...haahah oh well...let's see what happens next week
Didn't look until just NOW....but yes...it gapped....it's what's known as a GAP and CRAP....as opposed to a GAP (down) and SNAP(up) which is always better :)
I know you're kidding....but seriously....I'm watching it
Getting other things to "fire off first"
ha....i doubt you are poor. was just saying......ULU was gonna come back after they signed i-bank advisors. you know they caused this volume spike no no news.
Yup....I've been busy else where....ya got me there. Man, now I'm poor.
lololol...
today is the 4th highest trading day for ULU in a year
I called that EOD wrong...oops. Let's see what tommorow does. Going to hold till tommorow. Let the scanners pick up the volume tonight
cough cough I TOLD YOU SO. cough cough i'll be right on that pink i told you to buy too. dumar 2 derby 0
Yep. Actually, ULU is just equal to $0.06 (pre-split) currently, extremely low.
I'm looking for $1.5 (or $0.1 pre-split) to $2 ( or $0.13 pre-split) short term. With only 5.8 m S/O, it can go there in minutes.
Mid August the next Q should be out...they said sales have picked up in the last q report and would be reported in this Q. ok done posting here for now. Holding
This should be at 1.20 soon...see the 8k on the 14th of june.
.08X15 = $1.20 for the conversion feature of the convertable debt...I'm guessing we will be there by EOD...might have to adjust that to tommorow but we will see.
is my math right...5million shares? DAMN!!!
right now people are cashing in on those cheap shares...as soon as they are done this will move...maybe 2 or 3pm today...watch.
ULU is going to Run like ORS and SINO:
ORS went to $7.5 from $1.
SINO went to $9.15 from $1.7.
Both ORS and SINO have low S/O like ULU.
At the close of business on April 4, 2011, the record date for the Meeting, the number of our
outstanding shares of Common Stock that are entitled to vote was 87,341,709.
split that by 15 and you get 5,822,781: is that right? This think is tiny. This should be way higher right now
only for 500 shares though...hahah I got my money elsewhere but couldnt pass this one up
this hits a dollar...watch out. I call 1.20 today
Lots of news pending: Novartis, FDA, and China. With the float so low my guess is that any of them could spike the stock up to $2. What happens after that is anyones guess. Kerry was also doing a dog and pony show last week with the new investment firm so that may have something to do with it as well.
It'll be going to $1.5 or $0.1 (pre-split).
ULU, $0.7, just $0.045 (pre-split), S/O: 5.8 m, extremely low.
It was as high as $80 a few years back.
http://finance.yahoo.com/q/bc?s=ULU+Basic+Chart&t=5y
Strong buy!
if anyone gives them funding.....they will demand there is good reason for it go up
They can do as many r/splits and dilution they want. The gov't SEC give these guys loopholes of failing companies to continue to exist. It's a shame how the hard working dollar is the only one getting screwed. Look at GNTA for example. How many times are they allowed to suck people into their stock, drag it down then r/split taking more USD from hard working people. These companies are not to blame or the CEO's as many say, it's the system failed to deliver rules that make fk'n
COMMON SENSE
U or I go run a business like this it's called
BANKRUPTCY
This is just plain asinine!
yep i saw it today. i may get some soon enough. who knows?
.51 and trickling downhill....ugh what a nightmare for longs here
D MODE
Tempting, but when I put good money after bad I usually lose. I'll be watching, I would rather get in at .09 lol
Followers
|
30
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
801
|
Created
|
05/10/06
|
Type
|
Free
|
Moderators |
ULURU Inc. is an emerging specialty pharmaceutical company focused on the development of a portfolio of wound management, plastic surgery and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative transmucosal delivery system and Hydrogel Nanoparticle Aggregate technology
Contact information:
ULURU Inc.
4452 Beltway Drive
Addison, TX 75001
Tel: (214) 905-5145
Fax: (214) 905 5130
Website : www.uluruinc.com/
Stock Information:
Exchange : AMEX
SEC Filings : sec.gov/cgi-bin/browse-edgar
O/S : 65,582,532 as of March 16, 2009
Transfer Agent :
Continental Stock & Trust Co
17 Battery Place
New York, NY 10004-1123
Tel: 212-845-3212
Fax: 212-616-7616
Product Information:
www.altrazeal.com/
www.uluruinc.com/aphthasol.htm
The Wound, Ostomy and Continence Nurses Society (WOCN), St. Louis, MO, Jun 6-10
New Cardiovascular Horzizons, New Orleans, LA, July 9-12
American College of Foot & Ankle Orthopedics & Medicine (ACFAOM), Orlando, Florida, July 9-12
American Podiatric Medical Association (APMA), Toronto, CAN, July 30 - August 3
Symposium on Advanced Wound Care (SAWC) II, Wash DC, Sep 15-18
Diabet Limb Salvage, Wash DC, Sep 22-25
Clinical Symposium on Advances in Skin & Wound Care (CSASWC), San Antonio, TX, Oct 21-25
VA Podriatic Meeting, Nov
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |